Heparin Ratiopharm (Heparin Sodium)

Heparin Ratiopharm is indicated for the prevention and treatment of thromboembolic disorders where anticoagulation is required.

• Prevention of deep‑vein thrombosis (DVT) following surgery or prolonged immobilisation.
• Prophylaxis of pulmonary embolism in at‑risk patients.
• Treatment of acute coronary syndromes, including unstable angina.
• Management of clotting in patients undergoing haemodialysis or extracorporeal circuits.
• Adjunct therapy during cardiac surgery to maintain anticoagulation.

The safety profile of Heparin Ratiopharm reflects the typical effects observed with heparin sodium administered subcutaneously.

Common

• Minor bruising or bleeding at the injection site.
• Small haematomas or superficial skin erythema.
• Transient elevation of liver enzymes.
• Mild nausea or headache.

Serious

• Heparin‑induced thrombocytopenia (HIT) with a rapid drop in platelet count.
• Major bleeding events such as gastrointestinal or intracranial haemorrhage.
• Allergic reactions ranging from urticaria to anaphylaxis.

When prescribing Heparin Ratiopharm, clinicians should consider several precautionary measures to minimise risk.

• Assess baseline coagulation parameters and platelet count before initiating therapy.
• Adjust dose in patients with renal impairment or those receiving concurrent anticoagulants.
• Monitor for signs of bleeding, especially in the gastrointestinal or central nervous system.
• Avoid use in individuals with a known history of heparin‑induced thrombocytopenia.
• Use caution during pregnancy and lactation; evaluate risk‑benefit ratio.
• Re‑evaluate therapy regularly in elderly patients or those with hepatic dysfunction.

Heparin sodium may interact with a range of medications, influencing its anticoagulant effect.

Avoid

• Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) that markedly increase bleeding risk.
• Antiplatelet agents such as aspirin, clopidogrel, or non‑steroidal anti‑inflammatory drugs (NSAIDs).
• Thrombolytic drugs (e.g., alteplase, streptokinase).

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) at low doses, requiring close monitoring of bleeding.
• Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents that may impair platelet function.
• High‑dose corticosteroids, which can potentiate anticoagulant effects.